Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of idelalisib in patient with chronic lymphocytic leukemia or lymphoma relapsing after allogeneic hematopoietic cell transplantation

Trial Profile

Safety and efficacy of idelalisib in patient with chronic lymphocytic leukemia or lymphoma relapsing after allogeneic hematopoietic cell transplantation

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2017 As of June 22, 2017, a total of 28 patients had been registered according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 22 Dec 2017 New trial record
    • 12 Dec 2017 Results (n=24) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top